Japan's Taisho buys select Asian assets from Bristol-Myers

Japanese firm Taisho Pharmaceutical pays $310 million for six Asia-Pacific brands and the Indonesian business of Bristol-Myers, as it seeks to build its presence in the OTC drug market.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition